Ezabenlimab (Anti-PDCD1 / PD-1 / CD279) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. It can be used in the treatment of advanced solid tumors. MW :145.48 KD.